Analysts Issue Forecasts for Gilead Sciences Q1 Earnings

Gilead Sciences, Inc. (NASDAQ:GILD) – Investment analysts at Zacks Research lifted their Q1 2025 earnings per share estimates for shares of Gilead Sciences in a research note issued to investors on Monday, November 4th. Zacks Research analyst E. Bagri now expects that the biopharmaceutical company will earn $1.63 per share for the quarter, up from their prior estimate of $1.62. The consensus estimate for Gilead Sciences’ current full-year earnings is $3.75 per share. Zacks Research also issued estimates for Gilead Sciences’ Q3 2025 earnings at $2.04 EPS, Q4 2025 earnings at $1.80 EPS, Q1 2026 earnings at $1.62 EPS and Q3 2026 earnings at $2.11 EPS.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, August 8th. The biopharmaceutical company reported $2.01 EPS for the quarter, beating the consensus estimate of $1.61 by $0.40. Gilead Sciences had a return on equity of 29.34% and a net margin of 3.79%. The firm had revenue of $6.95 billion during the quarter, compared to the consensus estimate of $6.64 billion.

Several other equities analysts also recently issued reports on GILD. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $75.00 price target on shares of Gilead Sciences in a research note on Tuesday, October 29th. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $95.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, October 9th. Barclays lifted their target price on Gilead Sciences from $76.00 to $84.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Leerink Partnrs upgraded Gilead Sciences from a “hold” rating to a “strong-buy” rating in a research report on Monday, October 21st. Finally, Sanford C. Bernstein started coverage on Gilead Sciences in a research note on Thursday, October 17th. They issued an “outperform” rating and a $105.00 price objective on the stock. Ten equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and an average target price of $86.85.

Gilead Sciences Stock Up 1.6 %

Shares of NASDAQ GILD opened at $91.69 on Wednesday. Gilead Sciences has a 1 year low of $62.07 and a 1 year high of $91.98. The company has a debt-to-equity ratio of 1.18, a current ratio of 1.14 and a quick ratio of 0.95. The firm has a market cap of $114.15 billion, a PE ratio of 111.82, a price-to-earnings-growth ratio of 3.12 and a beta of 0.17. The company has a 50 day simple moving average of $84.58 and a 200 day simple moving average of $74.67.

Insiders Place Their Bets

In related news, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, insider Merdad Parsey sold 2,000 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.83, for a total value of $167,660.00. Following the completion of the sale, the insider now owns 100,189 shares in the company, valued at $8,398,843.87. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Johanna Mercier sold 29,357 shares of the firm’s stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the transaction, the insider now directly owns 78,127 shares in the company, valued at $6,545,480.06. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 36,847 shares of company stock worth $3,033,340. Insiders own 0.29% of the company’s stock.

Institutional Trading of Gilead Sciences

Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 2.6% during the 1st quarter. Vanguard Group Inc. now owns 114,732,575 shares of the biopharmaceutical company’s stock worth $8,404,161,000 after purchasing an additional 2,910,147 shares during the period. Swedbank AB bought a new stake in Gilead Sciences in the first quarter worth about $134,489,000. International Assets Investment Management LLC raised its position in Gilead Sciences by 8,238.4% in the third quarter. International Assets Investment Management LLC now owns 1,642,504 shares of the biopharmaceutical company’s stock worth $137,708,000 after acquiring an additional 1,622,806 shares during the period. Capital Research Global Investors boosted its stake in Gilead Sciences by 2.7% in the first quarter. Capital Research Global Investors now owns 61,246,366 shares of the biopharmaceutical company’s stock valued at $4,486,296,000 after acquiring an additional 1,589,240 shares during the last quarter. Finally, Pacer Advisors Inc. grew its position in shares of Gilead Sciences by 24.7% during the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after acquiring an additional 1,564,792 shares during the period. 83.67% of the stock is currently owned by institutional investors.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.